245 related articles for article (PubMed ID: 37579735)
21. A case paradoxical hidradenitis suppurativa with janus kinase inhibitor, literature review and pooled analysis of biological agent-induced HS.
Shaharir SS; Jamil A; Chua SH; Arumugam M; Rosli N
Dermatol Ther; 2020 Nov; 33(6):e14021. PubMed ID: 32677247
[TBL] [Abstract][Full Text] [Related]
22. Longitudinal observational study of hidradenitis suppurativa: impact of surgical intervention with adjunctive biologic therapy.
Shanmugam VK; Mulani S; McNish S; Harris S; Buescher T; Amdur R
Int J Dermatol; 2018 Jan; 57(1):62-69. PubMed ID: 29130482
[TBL] [Abstract][Full Text] [Related]
23. Two paradoxical reactions in a patient with psoriasis and psoriatic arthritis: Adalimumab-induced hidradenitis suppurativa and secukinumab-induced alopecia areata.
Öğüt ND
J Eur Acad Dermatol Venereol; 2023 Apr; 37(4):e468-e469. PubMed ID: 36151938
[No Abstract] [Full Text] [Related]
24. Advances in biologic and small molecule therapies for hidradenitis suppurativa.
Chen SX; Greif C; Gibson RS; Porter ML; Kimball AB
Expert Opin Pharmacother; 2022 Jun; 23(8):959-978. PubMed ID: 35470765
[TBL] [Abstract][Full Text] [Related]
25. Targeted treatments for hidradenitis suppurativa: a review of the current literature and ongoing clinical trials.
Maarouf M; Clark AK; Lee DE; Shi VY
J Dermatolog Treat; 2018 Aug; 29(5):441-449. PubMed ID: 29098911
[TBL] [Abstract][Full Text] [Related]
26. Biologic Use in Pediatric Patients With Hidradenitis Suppurativa: A Systematic Review.
Sachdeva M; Kim P; Mufti A; Maliyar K; Sibbald C; Alavi A
J Cutan Med Surg; 2022; 26(2):176-180. PubMed ID: 34587768
[TBL] [Abstract][Full Text] [Related]
27. Effects of adalimumab on T-helper-17 lymphocyte- and neutrophil-related inflammatory serum markers in patients with moderate-to-severe hidradenitis suppurativa.
Jiménez-Gallo D; de la Varga-Martínez R; Ossorio-García L; Collantes-Rodríguez C; Rodríguez C; Linares-Barrios M
Cytokine; 2018 Mar; 103():20-24. PubMed ID: 29289722
[TBL] [Abstract][Full Text] [Related]
28. Concomitant psoriasis and hidradenitis suppurativa responsive to adalimumab therapy: A case series.
Yen CF; Huang YH; Chi CC
Indian J Dermatol Venereol Leprol; 2021; 87(2):223-226. PubMed ID: 31389375
[TBL] [Abstract][Full Text] [Related]
29. Treatment of hidradenitis suppurativa with biologic medications.
Lee RA; Eisen DB
J Am Acad Dermatol; 2015 Nov; 73(5 Suppl 1):S82-8. PubMed ID: 26470624
[TBL] [Abstract][Full Text] [Related]
30. Clinical and Epidemiological Characteristics of Hidradenitis Suppurativa Patients with Paradoxical Psoriasiform Reactions following Treatment with Adalimumab.
Kanelleas A; Efthymiou O; Routsi E; Sgouros D; Pappa G; Tsoureli Nikita E; Bozi E; Katoulis A
Skin Appendage Disord; 2022 Sep; 8(5):415-418. PubMed ID: 36161088
[TBL] [Abstract][Full Text] [Related]
31. Guselkumab in the treatment of concomitant hidradenitis suppurativa, psoriasis, and Crohn's disease.
Berman HS; Villa NM; Shi VY; Hsiao JL
J Dermatolog Treat; 2021 Mar; 32(2):261-263. PubMed ID: 31389737
[TBL] [Abstract][Full Text] [Related]
32. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Sbidian E; Chaimani A; Garcia-Doval I; Doney L; Dressler C; Hua C; Hughes C; Naldi L; Afach S; Le Cleach L
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD011535. PubMed ID: 33871055
[TBL] [Abstract][Full Text] [Related]
33. Secukinumab in the treatment of hidradenitis suppurativa.
Snyder CL; Gibson RS; Porter ML; Kimball AB
Immunotherapy; 2023 Dec; 15(17):1449-1457. PubMed ID: 37840286
[TBL] [Abstract][Full Text] [Related]
34. Safety of Adalimumab Dosed Every Week and Every Other Week: Focus on Patients with Hidradenitis Suppurativa or Psoriasis.
Ryan C; Sobell JM; Leonardi CL; Lynde CW; Karunaratne M; Valdecantos WC; Hendrickson BA
Am J Clin Dermatol; 2018 Jun; 19(3):437-447. PubMed ID: 29380251
[TBL] [Abstract][Full Text] [Related]
35. An evaluation of secukinumab for the treatment of moderate-to-severe hidradenitis suppurativa.
Stergianou D; Kanni T; Damoulari C; Giamarellos-Bourboulis EJ
Expert Opin Biol Ther; 2024 Apr; 24(4):225-232. PubMed ID: 38602836
[TBL] [Abstract][Full Text] [Related]
36. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Sbidian E; Chaimani A; Garcia-Doval I; Doney L; Dressler C; Hua C; Hughes C; Naldi L; Afach S; Le Cleach L
Cochrane Database Syst Rev; 2022 May; 5(5):CD011535. PubMed ID: 35603936
[TBL] [Abstract][Full Text] [Related]
37. Adalimumab (antitumour necrosis factor-α) treatment of hidradenitis suppurativa ameliorates skin inflammation: an in situ and ex vivo study.
van der Zee HH; Laman JD; de Ruiter L; Dik WA; Prens EP
Br J Dermatol; 2012 Feb; 166(2):298-305. PubMed ID: 22013960
[TBL] [Abstract][Full Text] [Related]
38. Guselkumab effectiveness, and posology in patients with moderate to severe hidradenitis suppurativa: A retrospective bicentric experience.
Melgosa Ramos FJ; García Ruiz R; Mateu Puchades A; Alfageme Roldán F
Dermatol Ther; 2022 Jul; 35(7):e15558. PubMed ID: 35510581
[TBL] [Abstract][Full Text] [Related]
39. Paradoxical psoriasiform reactions to antitumour necrosis factor-α drugs in hidradenitis suppurativa.
Dequidt L; Cogrel O; Guillet S; Milpied B; Darrigade AS; Beylot-Barry M; Pham-Ledard A
Br J Dermatol; 2018 Jan; 178(1):281-283. PubMed ID: 28444990
[No Abstract] [Full Text] [Related]
40. Tumor necrosis factor-alpha inhibitor-induced psoriasis or psoriasiform exanthemata: first 120 cases from the literature including a series of six new patients.
Wollina U; Hansel G; Koch A; Schönlebe J; Köstler E; Haroske G
Am J Clin Dermatol; 2008; 9(1):1-14. PubMed ID: 18092839
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]